Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Immersive tours boost growth in China's tourismChinese entertainment projects receive global awards for outstanding achievementCultural Site of Han Dynasty in Xuzhou4 dead, 10 missing in Guangdong rainstormTheme park operator offers holiday treatsReal Madrid can clinch Spanish league title as it seeks another Champions League crownIce and snow warm up winter tourism in Northeast ChinaIce and snow warm up winter tourism in Northeast ChinaJapan says a collision during a nighttime drill caused the deadly April crash of 2 navy helicoptersChina's largest saltwater lake sees more water birds
2.3174s , 4666.8359375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Stellar Series news portal